Travelers warned about Oropouche virus in South American countries

Heading south for the winter? Oropouche virus, a new infectious disease, has been reported in travelers from Canada and the United States who visited Bolivia, Brazil, Peru, and Cuba. An article published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241440 provides an overview of this emerging virus.

Similar to viruses like dengue and Zika, Oropouche virus symptoms include fever, chills, headache, and muscle aches. The incubation period is 3–10 days, and symptoms last 2–7 days and may recur weeks later in some people. The virus is transmitted by small biting midges and some mosquitos. Wearing long-sleeved clothing and using mosquito nets and insect repellents containing DEET can help prevent infection.

There are currently no vaccines or antivirals to prevent or treat Oropouche virus. Acetaminophen is recommended for symptom relief; nonsteroidal anti-inflammatory medications should not be used.

As with Zika virus, in pregnant people, Oropouche virus may cause miscarriage and microcephaly. Given these risks, The Public Health Agency of Canada recommends that travellers take precautions to avoid insect bites, and that pregnant people or people planning pregnancy consider deferring travel to areas with Oropouche outbreaks.

Source:
Journal reference:

Dinh, T., et al. (2025). Oropouche virus. Canadian Medical Association Journal. doi.org/10.1503/cmaj.241440.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Updated guidelines for preventing and managing hepatitis B virus reactivation